CA2873229A1 - Treatment of multiple sclerosis with combination of laquinimod and fampridine - Google Patents

Treatment of multiple sclerosis with combination of laquinimod and fampridine Download PDF

Info

Publication number
CA2873229A1
CA2873229A1 CA2873229A CA2873229A CA2873229A1 CA 2873229 A1 CA2873229 A1 CA 2873229A1 CA 2873229 A CA2873229 A CA 2873229A CA 2873229 A CA2873229 A CA 2873229A CA 2873229 A1 CA2873229 A1 CA 2873229A1
Authority
CA
Canada
Prior art keywords
amount
laquinimod
fampridine
administered
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2873229A
Other languages
English (en)
French (fr)
Inventor
Joel Kaye
Nora Tarcic
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Original Assignee
Teva Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd filed Critical Teva Pharmaceutical Industries Ltd
Publication of CA2873229A1 publication Critical patent/CA2873229A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA2873229A 2012-07-12 2013-07-11 Treatment of multiple sclerosis with combination of laquinimod and fampridine Abandoned CA2873229A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261670758P 2012-07-12 2012-07-12
US61/670,758 2012-07-12
PCT/US2013/050001 WO2014011827A1 (en) 2012-07-12 2013-07-11 Treatment of multiple sclerosis with combination of laquinimod and fampridine

Publications (1)

Publication Number Publication Date
CA2873229A1 true CA2873229A1 (en) 2014-01-16

Family

ID=49914160

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2873229A Abandoned CA2873229A1 (en) 2012-07-12 2013-07-11 Treatment of multiple sclerosis with combination of laquinimod and fampridine

Country Status (17)

Country Link
US (2) US20140017226A1 (enExample)
EP (1) EP2872217A4 (enExample)
JP (1) JP2015522077A (enExample)
KR (1) KR20150038072A (enExample)
CN (1) CN104582793A (enExample)
AR (1) AR091724A1 (enExample)
AU (1) AU2013290181A1 (enExample)
BR (1) BR112015000616A2 (enExample)
CA (1) CA2873229A1 (enExample)
EA (1) EA201590191A1 (enExample)
HK (1) HK1209672A1 (enExample)
IL (1) IL236230A0 (enExample)
MX (1) MX2015000485A (enExample)
PY (1) PY1330684A (enExample)
TW (1) TW201408300A (enExample)
UY (1) UY34896A (enExample)
WO (1) WO2014011827A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013116657A1 (en) 2012-02-03 2013-08-08 Teva Pharmaceutical Industries Ltd. USE OF LAQUINIMOD FOR TREATING CROHN'S DISEASE PATIENTS WHO FAILED FIRST-LINE ANTI-TNFα THERAPY
MX2014009889A (es) 2012-02-16 2014-11-13 Teva Pharma N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinoli ncarboxamida, preparacion y usos de los mismos.
TW201410244A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
EA201590788A1 (ru) 2012-11-07 2015-12-30 Тева Фармасьютикал Индастриз Лтд. Аминные соли лахинимода
JP2016514162A (ja) 2013-03-14 2016-05-19 テバ ファーマシューティカル インダストリーズ リミティド ラキニモドナトリウムの結晶およびその製造のための改善された方法
HK1231413A1 (zh) 2014-04-29 2017-12-22 Teva Pharmaceutical Industries Ltd. 用於治疗具有高残疾状况的复发-缓解型多发性硬化症(rrms)的患者的拉喹莫德
GB2540163A (en) * 2015-07-07 2017-01-11 Univ London Queen Mary Combination therapy for treating multiple sclerosis
WO2022150349A1 (en) * 2021-01-06 2022-07-14 The Penn State Research Foundation Methods and materials for treating bone loss

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9726339D0 (en) * 1997-12-13 1998-02-11 Zeneca Ltd Human-derived tissue-specific potassium channel
US20090082471A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched fingolimod
ES2329327B1 (es) * 2008-03-19 2010-09-17 Proyecto De Biomedicina Cima, S.L. Combinaciones sinergicas de 5'-metiltioadenosina.
CN101827522A (zh) * 2008-09-10 2010-09-08 阿索尔达治疗股份有限公司 持续释放氨基吡啶组合物的使用方法
NZ597378A (en) * 2009-06-19 2014-08-29 Teva Pharma Treatment of multiple sclerosis with laquinimod
SG11201401330YA (en) * 2011-10-12 2014-05-29 Teva Pharma Treatment of multiple sclerosis with combination of laquinimod and fingolimod

Also Published As

Publication number Publication date
EA201590191A1 (ru) 2015-06-30
IL236230A0 (en) 2015-01-29
US20160235735A1 (en) 2016-08-18
PY1330684A (es) 2016-06-01
HK1209672A1 (en) 2016-04-08
KR20150038072A (ko) 2015-04-08
WO2014011827A1 (en) 2014-01-16
EP2872217A1 (en) 2015-05-20
TW201408300A (zh) 2014-03-01
CN104582793A (zh) 2015-04-29
AU2013290181A1 (en) 2015-02-26
JP2015522077A (ja) 2015-08-03
MX2015000485A (es) 2015-04-08
BR112015000616A2 (pt) 2017-06-27
AR091724A1 (es) 2015-02-25
US20140017226A1 (en) 2014-01-16
EP2872217A4 (en) 2016-03-16
UY34896A (es) 2014-02-28

Similar Documents

Publication Publication Date Title
US20170319570A1 (en) Treatment of Multiple Sclerosis With Combination of Laquinimod and Dimethyl Fumarate
US20160235735A1 (en) Treatment of multiple sclerosis with combination of laquinimod and fampridine
US20160166648A1 (en) Treatment of Multiple Sclerosis With Combination of Laquinimod and Interferon-Beta
CA2851525A1 (en) Treatment of multiple sclerosis with combination of laquinimod and fingolimod
HK1226940A1 (zh) 用拉喹莫德与醋酸格拉替雷的组合治疗多发性硬化症
WO2017048457A1 (en) Combination of laquinimod and pridopidine to treat multiple sclerosis
US20170007596A1 (en) Treatment of multiple sclerosis with combination of laquinimod and flupirtine
EP3229786A1 (en) Treatment of multiple sclerosis with combination of laquinimod and a statin
US20160184428A1 (en) Treatment of multiple sclerosis by alemtuzumab induction followed by laquinimod therapy
HK1224600A1 (en) Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate
CA2933541A1 (en) Treatment of multiple sclerosis with combination of laquinimod and teriflunomide

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20180711